| Drug Name |
Glycine betaine |
| Drug ID |
BADD_D02458 |
| Description |
Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine and reduces homocystinuria in patients with inborn errors of methionine metabolism. In the United States, betaine is distributed under the brand name Cystadane® by Rare Disease Therapeutics. Many reports have shown that betaine's therapeutic effectiveness is limited, and does not lower tHcy levels or prevent clinical symptoms [2]. |
| Indications and Usage |
Betaine is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: 1. cystathionine beta-synthase (CBS), 2. 5,10-methylenetetrahydrofolate reductase (MTHFR), 3. cobalamin cofactor metabolism (cbl). |
| Marketing Status |
Not Available |
| ATC Code |
A16AA06 |
| DrugBank ID |
DB06756
|
| KEGG ID |
D07523
|
| MeSH ID |
D001622
|
| PubChem ID |
247
|
| TTD Drug ID |
D0XB8P
|
| NDC Product Code |
52276-400; 55792-002 |
| Synonyms |
Betaine | Lycine | Oxyneurine | Glycine Betaine | Betaine, Glycine | Betaine Hydrochloride | Hydrochloride, Betaine | Cystadane | Novobetaine | Hepastyl | C.B.B. | Citrate de Bétaïne Beaufour | Citrate de Bétaïne UPSA | Stea-16 | Stea 16 | Stea16 | Acidin-Pepsin | Acidin Pepsin | AcidinPepsin | Scorbo-bétaïne | Scorbo bétaïne | Scorbobétaïne |
